深圳信立泰药业股份有限公司 王学恭，中国国籍，无境外居留权，男，1972 年生，大学本科，具备医药工 程师资格，现任公司独立董事，董事会提名委员会召集人、薪酬与考核委员会委 员。 1993 年 7 月至 2010 年 2 月，历任华北制药集团有限责任公司技术员、总经 理办公室副主任、营销战略部部长、资本运营部部长；2010 年 2 月至 2014 年 4 月任中国医药企业管理协会副秘书长，2014 年 4 月至今任中国医药企业管理协 会副会长。2016 年 4 月至 2021 年 5 月任人福医药集团股份公司独立董事，2017 年 5 月至 2023 年 6 月任北京诚益通控制工程科技股份有限公司独立董事，2020 年 9 月至今任迪哲（江苏）医药股份有限公司独立董事，2022 年 5 月至今任浙 江华海药业股份有限公司独立董事。2021 年 12 月至今任深圳信立泰药业股份有 限公司独立董事。 2017 年 5 月至 2024 年 12 月任中国医药包装协会副会长，2018 年 7 月至今 任三一创新（北京）投资管理有限公司合伙人、投资决策委员会成员，2018 年 9 月至今任杭州尚健生物技术有限公司董事， ...

一、 基本情况 （一） 个人工作履历、专业背景及兼职情况说明 刘来平，中国国籍，无境外居留权，男，1970 年生，法学博士，现任公司独 立董事，董事会薪酬与考核委员会召集人、提名委员会委员、审计委员会委员。 1993 年 7 月至 2003 年 5 月，历任深圳市龙岗区人民法院书记员、代理审判 员、审判员、执行庭副庭长；2003 年 5 月至 2013 年 8 月，历任深圳市中级人民 法院代理审判员、审判员、副处长、庭长、审判委员会委员。自 2014 年起担任 深圳迈瑞生物医疗电子股份有限公司中国区法律事务部总经理等职务，现任迈瑞 医疗副总经理。2022 年 6 月至 2024 年 1 月任深圳迈瑞科技控股有限责任公司董 事。2014 年 9 月至 2021 年 9 月任广东冠豪高新技术股份有限公司独立董事， 2016 年 9 月至 2022 年 10 月任深圳市海王生物工程股份有限公司独立董事。2020 年 1 月至今任深圳信立泰药业股份有限公司独立董事。 （二） 是否存在影响独立性的情况说明 深圳信立泰药业股份有限公司 2024 年度独立董事述职报告 各位股东及股东代表： 本人作为深圳信立泰药业股份有限公 ...

深圳信立泰药业股份有限公司 2024 年度独立董事述职报告 各位股东及股东代表： 作为公司独立董事，经自查，本人未在公司担任除独立董事以外的任何职务， 也未在公司主要股东公司担任任何职务，与公司及主要股东之间不存在利害关系 或其他可能妨碍本人进行独立客观判断的关系，亦不存在其他影响独立董事独立 性的情况。本人任职符合《上市公司独立董事管理办法》第六条等规定的独立性 要求，不存在影响独立性的情况。 二、 年度履职概况 | 独立董事 | 应参加 | 现场 | 以通讯方式 | 委托 | 缺席次数 | 是否连续 两次未亲自 | | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 会议次数 | 出席次数 | 参加次数 | 出席次数 | | | | | | | | | | 参加会议 | | 朱厚佳 | 5 | 2 | 3 | 0 | 0 | 否 | （一） 2024 年，公司共召开 5 次董事会，具体出席情况见下表： 本人作为深圳信立泰药业股份有限公司（下称"公司"）独立董事，2024 年 度，严格按照《公司法》、《上市公司独立董事管理办法》、《深圳证券交易所 上市公司自 ...

Product Development and Innovation - In 2024, the company launched two new drugs, Xintaitin and Fulitan, which have been approved for market and included in the medical insurance negotiations, establishing a solid foundation for sustainable development[11]. - The company has four exclusive and high-quality innovative patented products, with four new products currently under review for market approval and three in phase III clinical trials[11]. - The company is focusing on chronic disease management, particularly in the hypertension sector, with multiple innovative products launched and a rich pipeline of ongoing research[11]. - The company is conducting international multi-center phase II clinical trials for JK07 in the US, Canada, and China, showing promising safety and efficacy signals[11]. - The company has made significant progress in early-stage projects in both chemical and biological drug series, indicating steady advancement in innovation[11]. - The innovative drug Xinlitai (Alisartan) has been included in the national medical insurance directory after three rounds of negotiations, enhancing its market potential[39]. - The new product sales, including Xinlitai and Fuzhitai, have shown rapid growth, contributing to the company's sustained growth momentum[46]. - The innovative drug Ennaruo (HIF-PHI) was included in the national medical insurance directory in 2023, targeting anemia in non-dialysis chronic kidney disease patients[42]. - The clinical research for the innovative drug S086 has shown significant dose-dependent blood pressure reduction, with reductions of 25.07 mmHg and 28.22 mmHg for 240 mg and 480 mg doses respectively after 12 weeks[40]. - Four key R&D projects have successfully completed their milestone goals, with S086 (hypertension) passing technical review and several other drugs in the CDE review process[50]. - The company plans to submit 7 drug IND applications and 2 new product market applications in 2024, along with 5 clinical trial approvals and 5 registration certificates[54]. - The company has been granted 69 patents, including 46 invention patents, and has submitted 178 new patent applications, indicating a strong focus on innovation[55]. - The company is actively exploring AI technology applications in drug discovery and clinical research to enhance efficiency and decision-making[52]. - The company has established a comprehensive chronic disease product pipeline, focusing on hypertension, heart failure, and chronic kidney disease, addressing unmet clinical needs[59]. - The Gstream® drug-eluting peripheral artery stent system has entered the "green channel" approval process, marking a significant advancement in medical device innovation[54]. - The company is expanding its product pipeline with new medical devices, including drug-eluting stents and balloon catheters for cardiovascular interventions[86]. - The company is actively developing new drug compositions, including a combination drug for hypertension and heart failure, with applications expected in 2024[92]. Financial Performance - The company's operating revenue for 2024 reached ¥4,012,231,593.39, representing a 19.22% increase compared to ¥3,365,343,342.73 in 2023[27]. - The net profit attributable to shareholders for 2024 was ¥601,569,140.20, a 3.71% increase from ¥580,066,240.84 in 2023[27]. - The net cash flow from operating activities increased by 41.32% to ¥1,186,258,420.75 in 2024, up from ¥839,442,557.56 in 2023[27]. - Total assets at the end of 2024 were ¥10,465,603,624.18, an 11.38% increase from ¥9,396,672,754.02 at the end of 2023[27]. - The company reported a basic earnings per share of ¥0.54 for 2024, a 3.85% increase from ¥0.52 in 2023[27]. - The net profit after deducting non-recurring items for 2024 was ¥570,202,532.66, an 8.43% increase from ¥525,862,387.30 in 2023[27]. - The pharmaceutical manufacturing sector contributed ¥3,706,825,061.65, accounting for 92.39% of total revenue, with a year-on-year growth of 17.69%[66]. - The medical device segment saw a significant increase of 41.68%, generating ¥305,406,531.74, up from ¥215,562,619.48 in the previous year[66]. - The company achieved a gross margin of 73.40% in the pharmaceutical manufacturing sector, an increase of 4.00% year-on-year[68]. - Sales volume in the pharmaceutical manufacturing sector increased by 30.79% to 165,585,451 boxes in 2024, compared to 126,600,060 boxes in 2023[70]. - The company’s total sales revenue from the top five customers amounted to ¥2,053,359,796.30, representing 51.17% of the annual total sales[76]. Strategic Focus and Market Expansion - The company is focusing on the cardiovascular disease market, which has over 300 million patients in China, indicating significant growth potential[36]. - The company is expanding its product pipeline in chronic disease areas, including hypertension, heart failure, and metabolic diseases, with several competitive products in development[37]. - The company plans to leverage inter-departmental collaboration to enhance its offerings in various therapeutic areas, including oncology and mental health[37]. - The company has a strategic focus on innovation in pharmaceuticals and medical devices, aiming to provide comprehensive treatment solutions[37]. - The company aims to deepen its focus on the cardiovascular treatment field, establishing a strong customer base and brand reputation in specific segments[62]. - The company is committed to building a collaborative innovation ecosystem, integrating technology and talent development to enhance core competitiveness[52]. - The company is actively exploring new chronic disease management models and expanding its market presence through diversified channel strategies[47]. - The company is committed to internationalization and aims to establish itself as a leading innovative pharmaceutical enterprise based in China[128]. - The company is actively participating in volume-based procurement to strengthen its market competitiveness in the generic drug sector[129]. - The company plans to enhance its product commercialization capabilities and increase product penetration rates in 2025[129]. - Market expansion plans include entering two new international markets by the end of the year, targeting a 10% increase in overall market share[6]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of 500 million RMB allocated for potential deals[7]. Governance and Management - The company has established a comprehensive governance structure, with independent operation of the board of directors and supervisory board[162]. - The board of directors operates transparently and effectively, with independent directors playing a crucial role in protecting minority shareholder interests[144]. - The supervisory board consists of three members, including one employee representative, ensuring effective oversight of the company's operations[145]. - The company has implemented an employee stock ownership plan to enhance employee motivation and promote long-term sustainable development[146]. - The controlling shareholder has pledged 15.679 million shares, representing 24.68% of their total holdings and 14.06% of the company's total shares, indicating a relatively low pledge ratio[151]. - The company maintains a completely independent operational structure from its controlling shareholder, with separate assets, personnel, and financial management[158]. - The company has established a transparent performance evaluation and incentive mechanism for senior management, continuously optimizing it[146]. - The company actively engages with stakeholders, ensuring a balance of interests among shareholders, employees, and the community[148]. - The company has a dedicated financial department that operates independently, ensuring no interference from the controlling shareholder in financial activities[164]. - The company has held two shareholder meetings during the reporting period, ensuring equal rights for all shareholders, especially minority shareholders[143]. Research and Development - The company invested 1.017 billion yuan in R&D in 2024, accounting for 25.35% of its revenue[48]. - R&D investment amounted to ¥1,017,122,792.10 in 2024, down 2.90% from ¥1,047,475,745.11 in 2023[94]. - R&D investment as a percentage of revenue fell to 25.35% from 31.13%, a decrease of 5.78%[94]. - R&D personnel decreased to 755, a decline of 3.70% from 784[93]. - The company is prioritizing the development of smart medical devices, which are anticipated to improve patient outcomes and operational efficiency in healthcare settings[92]. - The company is focusing on optimizing production processes and enhancing operational efficiency to manage rising costs[133]. - The company anticipates risks related to high R&D costs, long cycles, and potential policy changes affecting drug pricing[132]. Sustainability and Corporate Responsibility - The company is committed to sustainability initiatives, aiming for a 40% reduction in carbon emissions by 2025[186]. - The company has committed to green development and resource conservation, contributing to sustainable development goals[148]. - The company has established a "Market Value Management System" to enhance investment value and shareholder returns, approved on March 23, 2025[135]. - The "Quality and Return Dual Improvement" action plan aims for high-quality development and investor returns, with a focus on chronic disease innovation[136]. - The company has actively implemented the "Quality and Return Dual Improvement" action plan, enhancing compliance and operational efficiency[137].

关于深圳信立泰药业股份有限公司 华英证券有限责任公司 华英证券有限责任公司（以下简称"华英证券"或 "保荐机构"）作为深圳 信立泰药业股份有限公司（以下简称"信立泰"或 "公司"）2020 年非公开发行 A 股股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司监管 指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年修订）》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等有关 规定，对信立泰使用闲置募集资金进行现金管理的情况进行了审慎核查。核查的 具体情况及核查意见如下： 一、募集资金及投资项目基本情况 经中国证券监督管理委员会证监许可[2021]663 号文核准《关于核准深圳信 立泰药业股份有限公司非公开发行股票的批复》，公司向特定投资者发行人民币 普通股 68,800,535 股，每股面值 1 元，每股发行价人民币 28.37 元。募集资金共 计人民币 195,187.12 万元，扣除不含税发行费用人民币 1,980.55 万元，实际募集 资金净额为人民币 193,206.57 万元。上述募集资金已于 2021 年 5 月 24 日全部到 位，并经大 ...

具体情况如下： 证券代码：002294 证券简称：信立泰 编号：2025-009 深圳信立泰药业股份有限公司 关于使用自有闲置资金投资理财产品的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、投资种类：公司将按照相关规定严格控制风险，对投资产品进行评估、 筛选，委托理财的投资种类应为符合《深圳证券交易所上市公司自律监管指引第 7 号——交易与关联交易》规定的理财产品。 2、投资金额：投资理财产品的金额在人民币 20 亿元以内，上述额度可由公 司及纳入公司合并报表范围内的子公司共同滚动使用，相关额度的使用期限不超 过 12 个月，期限内任一时点的交易金额不应超过委托理财额度。 3、特别风险提示：委托理财可能存在市场波动、政策风险、操作风险等风 险因素，投资收益具有不确定性。敬请广大投资者注意投资风险。 为提高自有资金使用效率，合理利用闲置资金，深圳信立泰药业股份有限公 司（下称"公司"）于 2025 年 3 月 23 日召开第六届董事会第八次会议，以 9 人 同意，0 人反对，0 人弃权，审议通过了《关于使用自有闲置资金投资理财产品 的 ...

证券代码：002294 证券简称：信立泰 编号：2025-008 深圳信立泰药业股份有限公司 第六届监事会第七次会议决议公告 一、会议以 3 人同意，0 人反对，0 人弃权，审议通过了《关于使用自有闲 置资金投资理财产品的议案》。 公司目前经营状况良好，运作规范。在保障流动性和资金安全的前提下，使 用人民币 20 亿元以内自有闲置资金，购买专业理财机构（包括但不限于银行、 信托、证券公司等）的理财产品，有利于提高资金使用效率，获得一定的投资收 益。该项决策履行了必要的程序，相关审批和决策程序符合法律法规及《公司章 程》等规定。 监事会同意公司及纳入公司合并报表范围内的子公司使用自有闲置资金人 民币 20 亿元以内，投资理财产品。在上述额度内，资金可以滚动使用，授权期 限为自董事会审议通过之日起一年内有效。 （《关于使用自有闲置资金投资理财产品的公告》详见信息披露媒体：《中 国证券报》、《证券时报》和巨潮资讯网 www.cninfo.com.cn。） 二、会议以 3 人同意，0 人反对，0 人弃权，审议通过了《关于使用部分闲 置募集资金现金管理的议案》。 监事会认为：在保证募集资金投资项目正常进行的情况下，公司 ...

深圳信立泰药业股份有限公司 第六届董事会第八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 证券代码：002294 证券简称：信立泰 编号：2025-007 深圳信立泰药业股份有限公司（下称"公司"）第六届董事会第八次会议于 2025 年 3 月 23 日，以书面方式召开，会议通知于 2025 年 3 月 16 日以电子邮件 方式送达。应参加董事 9 人，实际通过书面方式参加董事 9 人，出席董事符合法 定人数。本次会议召开符合法律法规和《公司章程》等有关规定。 与会董事审议并形成如下决议： 一、会议以 9 人同意，0 人反对，0 人弃权，审议通过了《关于使用自有闲 置资金投资理财产品的议案》。 为提高自有资金使用效率，合理利用闲置资金，同意公司在满足正常经营和 研发、生产、建设资金需求的情况下，根据自有闲置资金状况和投资经营计划， 购买专业理财机构（包括但不限于银行、信托、证券公司等）的理财产品。投资 理财产品的金额在人民币 20 亿元以内，上述额度可由公司及纳入公司合并报表 范围内的子公司共同滚动使用，相关额度的使用期限不超过 12 个月， ...

Investment Rating - The report initiates coverage with an "Accumulate" rating for the company [5][29]. Core Views - The company is deeply engaged in the cardiovascular field, with a stable cash flow from its generic drug business and multiple core innovative drugs recently approved, leading to an expected increase in the proportion of innovative revenue [3][29]. - The company is projected to achieve revenues of 40.1 billion, 44.2 billion, and 54.3 billion yuan for the years 2024, 2025, and 2026, respectively, with year-on-year growth rates of +19%, +10%, and +23% [14][21]. - The net profit attributable to the parent company is expected to be 6.4 billion, 6.9 billion, and 8.31 billion yuan for the same years, with year-on-year growth rates of +10%, +8%, and +20% [14][21]. Summary by Sections 1. Profit Forecast and Investment Recommendations - The company focuses on drug development in the chronic disease field, particularly cardiovascular diseases, with core products like Xinlitai, S086, and Ennadustat expected to contribute significantly to cash flow [21][29]. - The innovative drug revenue share is anticipated to increase as the company accelerates its transformation [21][29]. 2. Focus on Chronic Disease Field - The company has a comprehensive layout in the cardiovascular field, with a gradual clearing of the impact from centralized procurement, leading to stable cash flow from generic drugs [29][36]. - The innovative product pipeline is progressing steadily, with several new products expected to be launched soon [29][36]. 3. Commercial Potential of S086 and JK07 - The company maintains good growth with its core product Xinlitai, while S086 is expected to be a significant innovative product in the ARNI category, with a market potential exceeding 35 billion yuan [29][36]. - JK07, as a long-acting heart failure treatment, shows promising clinical data and is expected to read out complete Phase II data by Q4 2026 [29][36]. 4. Financial Summary - The company’s total revenue for 2022 was 3.48 billion yuan, with a net profit of 637 million yuan, and is projected to grow significantly in the coming years [14][21]. - The company has a total market capitalization of 33.266 billion yuan and a current price of 29.84 yuan, with a target price set at 35.33 yuan [5][6]. 5. Valuation Methods - The report employs both absolute and relative valuation methods, concluding a reasonable valuation of 35.33 yuan per share based on discounted cash flow (DCF) and comparable company analysis [23][27][29].